Neisseria meningitidis Serogroup W, Burkina Faso, 2012

Jessica R. MacNeil, Isaïe Medah, Daouda Koussoubé, Ryan T. Novak, Amanda C. Cohn, Fabien V.K. Diomandé, Denis Yelbeogo, Jean Ludovic Kambou, Tiga F. Tarbangdo, Rasmata Ouédraogo-Traoré, Lassana Sangaré, Cynthia Hatcher, Jeni Vuong, Leonard W. Mayer, Mamoudou H. Djingarey, Thomas A. Clark, and Nancy E. Messonnier

In 2010, Burkina Faso became the first country to introduce meningococcal serogroup A conjugate vaccine (PsA-TT). During 2012, Burkina Faso reported increases in Neisseria meningitidis serogroup W, raising questions about whether these cases were a natural increase in disease or resulted from serogroup replacement after PsA-TT introduction. We analyzed national surveillance data to describe the epidemiology of serogroup W and genotyped 61 serogroup W isolates. In 2012, a total of 5,807 meningitis cases were reported through enhanced surveillance, of which 2,353 (41%) were laboratory confirmed. The predominant organism identified was N. meningitidis serogroup W (62%), and all serogroup W isolates characterized belonged to clonal complex 11. Although additional years of data are needed before we can understand the epidemiology of serogroup W after PsA–TT introduction, these data suggest that serogroup W will remain a major cause of sporadic disease and has epidemic potential, underscoring the need to maintain high-quality case-based meningitis surveillance after PsA–TT introduction.

In Burkina Faso, which lies within the meningitis belt of sub-Saharan Africa, rates of endemic meningitis are high, seasonal epidemics occur each year, and explosive epidemics occur every 5–12 years (1,2). Historically, these epidemics have been caused primarily by Neisseria meningitidis serogroup A (3,4). During late 2010, Burkina Faso became the first country to introduce a novel meningococcal serogroup A polysaccharide–tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac (Serum Institute of India Ltd, Pune, India)). More than 11 million persons were vaccinated during ≈10 days in the eligible population of persons aged 1–29 years (4,5). Early evidence suggests that this aggressive strategy substantially reduced the rate of meningitis among persons in these age groups and in the general population because of high coverage and herd immunity (5). Since 2010, nine countries have implemented PsA-TT; the 100 millionth dose was given in December 2012.

Although N. meningitidis serogroup A has virtually disappeared in countries that have implemented nationwide vaccination campaigns, other serogroups, including N. meningitidis serogroup W and serogroup X, have the potential to cause epidemics. Sporadic disease and localized epidemics caused by serogroup X have been well described, but the potential of serogroup X to cause large epidemics remains unclear (6). During 2000 and 2001, serogroup W was associated with outbreaks in pilgrims to the Hajj and was followed by several clusters of cases worldwide (7–9). The largest reported outbreak caused by serogroup W occurred in Burkina Faso in 2002 and comprised ≈13,000 suspected cases (10). Sporadic cases and smaller outbreaks caused by serogroup W have continued to occur and have been described as occurring in several meningitis belt countries, including Burkina Faso (11–15). During 2012, Burkina Faso reported an increase in cases of serogroup W, raising questions about whether the increase resulted from a natural increase in disease or resulted from serogroup replacement after PsA-TT introduction. We analyzed national surveillance data and isolates from Burkina...
Faso to describe the epidemiology of serogroup W during 2012 and to assess changes and trends in serogroup W epidemiology around PsA-TT introduction.

Methods

Burkina Faso has 2 complementary systems of population-based meningitis surveillance (5). Surveillance for reportable diseases is conducted by the Télégramme Lettre Officiel Hebdomadaire (TLOH), to which district-level aggregate reports of clinically defined meningitis cases and meningitis-related deaths are transmitted weekly. Enhanced surveillance for Maladies à Potentiel Epidémique (MPE) collects case-level demographic information and results of cerebrospinal fluid (CSF) examination and laboratory testing. For this analysis, we used data from TLOH for 2007–2012 and MPE enhanced surveillance data for 2010–2012. All 63 districts reported suspected meningitis cases to both surveillance systems during 2010–2012. Aggregate laboratory testing results for the 2007–2009 meningitis seasons and enhanced surveillance data for the 2002 meningitis season also were analyzed.

We used a modified case definition to classify cases. Suspected cases of meningitis were defined as sudden onset of fever with a stiff neck or, in infants, a bulging fontanelle. Probable bacterial meningitis was defined as a suspected case for which gram-stained CSF was positive (gram-negative diplococci, gram-positive diplococci, or gram-negative bacilli); probable meningococcal meningitis cases are limited to those with gram-negative diplococci. A confirmed case of meningitis was defined as a suspected or probable case for which *N. meningitidis*, *Haemophilus influenzae* type b or *Streptococcus pneumoniae* was isolated in culture from blood or CSF, or antigen was detected in CSF by latex agglutination or PCR. Latex agglutination–positive cases that were later negative by PCR or culture were reclassified as suspected cases.

Beginning in 2010, real-time PCR capacity was implemented at the national reference laboratory, and detection of *N. meningitidis*, *H. influenzae* type b, or *S. pneumoniae* genetic material by PCR was deemed confirmatory (16,17). Serogroup was determined by antigen detection or by PCR, with PCR deemed definitive. Because serogroup Y is seen infrequently as a cause of disease in Burkina Faso, all specimens positive for serogroup Y/serogroup W by latex agglutination and not tested by PCR or culture were assumed to be serogroup W.

The meningitis season in Burkina Faso is limited to epidemiologic weeks 1–24. The pre–PsA-TT implementation period was defined as January 1, 2007–December 31, 2010, and the post–PsA-TT implementation period as January 1, 2011–December 31, 2012. Incidence rates were cumulative yearly incidence per 100,000 population and were calculated with national, regional, and district population estimates from the Institut National de la Statistique et de la Démographie. Districts crossed the World Health Organization weekly epidemic threshold when the weekly incidence rate exceeded 10 suspected cases per 100,000 population (18).

Multilocus sequence typing, porin A (PorA), and ferric enterobactin transport (FetA) genotyping was performed on 61 serogroup W isolates (6 from 2011 and 55 from 2012). Multilocus sequence typing was performed by sequencing the internal fragment of 7 housekeeping genes (19). PorA and FetA genotyping was performed by sequencing the variable regions (VRs) of *porA* (VR1 and VR2) and the VR of *fetA*. All generated sequencing data were analyzed by using the Web-based software MGIP (http://mgip.biology.gatech.edu/home.php). Molecular types (sequence type [ST], clonal complex [cc], PorA, and FetA) were determined by searching the PubMLST database (http://pubmlst.org). Strain genotype was defined as ST(cc):PorA:FetA.

Results

During January 1–December 31, 2012, a total of 7,022 suspected meningitis cases (739 [11%] fatal) were reported through TLOH in Burkina Faso, corresponding to an incidence of 42.0 cases per 100,000 population. A total of 5,807 cases were reported through MPE case-based meningitis surveillance; 2,353 (41%) were confirmed, 415 (7%) were probable, and 3,039 (52%) were suspected meningitis cases. Of the 2,353 confirmed cases, 591 (25%) were confirmed by culture, 1,741 (74%) by PCR, and 21 (<1%) by latex agglutination. The predominant organism identified was *N. meningitidis* serogroup W (Table 1). More meningitis cases were reported during the 2012 than the 2011 meningitis season, and a higher proportion of cases were caused by serogroup W in 2012 than in 2011 (Figure 1).

Of persons with *N. meningitidis* serogroup W infection during 2012, a total of 11% were <1 year of age, 29% were 1–4 years, 29% were 5–9 years, 16% were 10–14 years, and 15% were ≥15 years. This distribution is similar to that during the 2011 meningitis season.

Table 1. Laboratory-confirmed bacterial meningitis cases, Burkina Faso, 2012*

| Bacterium, serogroup | Culture or PCR | Latex agglutination† | Total |
|----------------------|----------------|----------------------|-------|
| *Neisseria meningitidis* |               |                      |       |
| A                    | 0              | 0                    | 0     |
| W                    | 1,438          | 13                   | 1,451 |
| X                    | 207            | NA                   | 207   |
| Y                    | 4              | 0                    | 4     |
| C                    | 1              | 0                    | 1     |
| Indeterminate       | 125            | 0                    | 125   |
| *Streptococcus pneumoniae* | 527          | 7                    | 534   |
| *Haemophilus influenzae* type b | 30       | 1                    | 31    |
| Total                | 2,332          | 21                   | 2,353 |

*Data are from Maladies à Potentiel Epidémique case-based surveillance. NA, not applicable.†Excludes 62 latex agglutination–positive cases that were later ruled out by PCR and/or culture.
for serogroup W cases during the 2002 serogroup W epidemic, according to enhanced surveillance data (serogroup W: 16% were <1 year of age, 28% were 1–4 years, 31% were 5–9 years, 8% were 10–14 years, and 17% were ≥15 years). The incidence of laboratory-confirmed serogroup W was 8.7 cases per 100,000 population in 2012, compared with 0.7 per 100,000 in 2011. During 2007–2010, when <15% of cases were laboratory confirmed, the incidence of serogroup W was <0.1 cases per 100,000 population (Table 2).

The incidence of serogroup W varied by district, from 0.0 to 40.7 cases per 100,000 population (median 6.1/100,000) in 2012. By week 24, thirteen districts had crossed the weekly epidemic threshold of 10 suspected cases per 100,000 population (selected districts, Figure 2); *N. meningitidis* serogroup W was the predominant serogroup identified in 12 of these 13 districts (*N. meningitidis* serogroup X was the predominant organism identified in the 13th district). In no district did the cumulative incidence rate reach >100 cases per 100,000 population, the established definition of an epidemic, during 2012 (20). Three districts had reactive vaccination campaigns that used quadrivalent (A, C, W, Y) polysaccharide vaccine; in 2 of these districts, the number of cases crossed the weekly epidemic threshold. These districts were 2 of the last to cross the weekly epidemic threshold in 2012 during weeks 14 and 15. Cumulative incidence of serogroup W cases in these districts was 11.0 and 23.2 cases per 100,000 population, respectively.

We characterized 61 serogroup W isolates: 6 from 2011 and 55 from 2012, all belonging to cc11. The predominant genotype detected was ST-11(cc11):P1.5,2:F1–1, which accounted for 90% (55/61) of the total isolates. The remaining isolates differed only in the FetA and ST (ST-11[cc11]:P1.5,2:F6–3, 2/61 [3%]; ST-2961[cc11]:P1.5,2:F1–1, 2/61 [3%]); and ST-9766[cc11]:P1.5,2:F1–1, 2/61 [3%]). Three STs were detected: ST-11 (57/61 [93%]), ST-2961 (2/61 [3%]), and ST-9766 (2/61 [3%]).

**Discussion**

In 2012, the second year after PsA-TT introduction in Burkina Faso, the continued absence of serogroup A demonstrated the effect of this enormously successful vaccination campaign. *N. meningitidis* serogroup W was the predominant organism causing meningitis during the 2012 epidemic season. However, rates of serogroup W disease were substantially lower in 2012 (8.7 cases/100,000 population [Table 2]) than during the 2002 epidemic, when attack rates were ≈100–250 cases per 100,000 population (10,21).

![Figure 1. Laboratory-confirmed bacterial meningitis cases and *Neisseria meningitidis* serogroup W cases, Burkina Faso, 2011 and 2012 meningitis seasons. Data source: Maladies à Potentiel Epidémique (case-based surveillance).](image-url)

**Table 2. Bacterial meningitis cases and incidence, Burkina Faso, 2007–2012**

| Variable | Prevaccine | Postvaccine |
|----------|------------|-------------|
|          | 2007       | 2008        | 2009 | 2010 | 2011 | 2012 |
| Total no. cases reported in MPE | NA | NA | NA | 3,413 | 3,415 | 5,807 |
| Total no. specimens tested in aggregated laboratory results | 550 | 93 | 241 | NA | NA | NA |
| Confirmed or probable cases, no. | 286 | 52 | 139† | 1,408 | 1,306 | 2,768 |
| *Neisseria meningitidis*, no. cases (Incidence): | 257 (1.8) | 49 (0.3) | 43 (0.3) | 170 (1.1) | 278 (1.7) | 1,788 (10.7) |
| *N. meningitidis* serogroup W, no. cases (Incidence): | 4 (<0.1) | 0 | 4 (<0.1) | 10 (<0.1) | 113 (0.7) | 1,451 (8.7) |
| Total cases reported in TLOH | 25,695 | 10,345 | 4,878 | 6,837 | 3,878 | 7,022 |

*Incidence = cases per 100,000 population. MPE, Maladies à Potentiel Epidémique (case-based surveillance); NA, not available; TLOH, Télégramme Lettre Official Hebdomadaire (aggregate case counts).† Only latex agglutination results available.
The serogroup W clone associated with the Hajj-related outbreak during 2000 (22) has been present and a persistent cause of sporadic disease in Burkina Faso since the 2002 epidemic (R. Ouédraogo-Traoré, pers. comm.). The increase in serogroup W during 2012 might represent a natural increase in disease associated with waning population immunity in the 10 years since the last epidemic. This hypothesis is supported by the high proportion of serogroup W infections among younger children and the characterization of most serogroup W strains from 2012 as ST-11(cc11):P1.5,2:F1–1, the same genotype as the clone that caused the 2002 epidemic (11,22).

In Burkina Faso, rates of nasopharyngeal carriage of serogroup W are low (23). A previous study from Burkina Faso during the 2002 serogroup W epidemic demonstrated that serogroup W carriage infrequently induces protective immunity and that natural immunity against serogroup W may be lost (24). Serogroup replacement after nationwide vaccination with PsA-TT cannot be ruled out, however, and additional years of surveillance data, as well as nasopharyngeal carriage surveys, are required for a full understanding of whether serogroup replacement has resulted from PsA-TT vaccination. Preliminary data indicate that rates of serogroup W disease were lower during the 2013 meningitis season than during the 2012 meningitis season.

*N. meningitidis* has multiple genetic mechanisms to alter its antigenic profile, including capsular switching. Capsular switching has been observed among pneumococcal serotypes after the 7-valent pneumococcal conjugate vaccine was introduced in the United States, although the substantial declines in incidence of pneumococcal disease were maintained overall (25). Immediately after implementation of serogroup C meningococcal conjugate vaccine in the United Kingdom, no evidence of capsular replacement was found (26). Low rates of serogroup C disease in the United Kingdom have persisted, but serogroup Y has increased during the past several years in the United Kingdom and several other European countries (27). However, the effects of vaccination often are difficult to disentangle from natural fluctuations in meningococcal incidence and serogroup distribution.

With the recent shift in the epidemiology of bacterial meningitis in Burkina Faso after PsA-TT introduction, the current epidemic thresholds for predicting meningitis epidemics should be reevaluated. Although both serogroup W and serogroup X are known to cause epidemics, neither has been observed to cause the explosive epidemics of serogroup A or to have the periodicity observed for serogroup A epidemics. These thresholds were developed when the effects of disease were substantially higher so that epidemics could be anticipated and response activities (i.e., reactive vaccination campaigns) would prevent additional cases (18). In the 13 districts in Burkina Faso where meningitis reached the weekly epidemic threshold during 2012, the peak of reported cases was detected (Figure 2), but in no district was the cumulative annual epidemic threshold of 100 cases per 100,000 population met (20). During the 2012 meningitis season, 3 districts in Burkina Faso had vaccination campaigns that used quadrivalent polysaccharide vaccine. These are the first campaigns to use quadrivalent polysaccharide vaccine after PsA-TT vaccine; how many additional serogroup W cases were prevented and how administration of polysaccharide vaccination after PsA-TT will affect duration of protection against serogroup A disease are unknown.

---

**Figure 2.** Total meningitis cases reported in Télégramme Lettre Officiel Hebdomadaire and laboratory-confirmed *Neisseria meningitidis* serogroup W cases for selected districts, Burkina Faso, 2012 meningitis season. A) District 1, population 150,000. B) District 2, population 300,000. C) District 3, population 100,000. D) District 4, population 200,000. Thin line indicates serogroup W cases; thick line, total cases; • indicates weeks during which the number of cases crossed the weekly epidemic threshold. Data source: Télégramme Lettre Officiel Hebdomadaire and Maladies à Potentiel Epidémique.
The increases in serogroup W disease during 2012 were recognized because of the investment in high-quality meningitis surveillance in Burkina Faso, which underscores the importance of maintaining high-quality case-based meningitis surveillance capacity across the meningitis belt after PsA-TT introduction. Although additional years of data are needed to understand the epidemiology of meningococcal disease after PsA-TT introduction, it is evident that N. meningitidis will continue to cause sporadic disease and has potential to cause epidemics. In the meantime, countries need to effectively communicate the need for persons to remain diligent about seeking care for meningitis symptoms while not undermining public trust in the effectiveness of PsA-TT. The only available control strategy for serogroup W epidemics is reactive campaigns with trivalent or quadrivalent meningococcal polysaccharide vaccine. An affordable, multivalent vaccine, developed for use in the meningitis belt is needed in this disproportionately affected region to protect against epidemic meningitis.

Acknowledgments
We thank the residents and health care workers of Burkina Faso for their participation in the surveillance of meningitis. We thank the public health workers at the Direction de la Prevention par la Vaccination, the Direction de la Lutte contre la Maladie, World Health Organization (WHO) country office, WHO Inter-country Support Team for West Africa, WHO Regional Office for Africa, and WHO Headquarters for their contributions.

Ms MacNeil is an epidemiologist in the Meningitis and Vaccine Preventable Diseases Branch at the US Centers for Disease Control and Prevention. Her primary research interests are the prevention and control of meningococcal disease.

References
1. Lapeyssonnie L. Cerebrospinal meningitis in Africa [in French]. Bull World Health Organ. 1963;28(Suppl):1–114.
2. Greenwood B. Manson lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg. 1999;93:341–53. http://dx.doi.org/10.1016/S0035-9203(99)90106-2
3. Djingarey MNS, Preziosi MP. A 20-year retrospective analysis of epidemic meningitis surveillance data in Burkina Faso, Mali, and Niger. 16th International Pathogenic Neisseria Conference; 2008 Sep 7–12; Rotterdam, the Netherlands; 2008. p. P166 [cited 2013 Dec 27]. http://neisseria.org/ipmc/2008/abstracts_poster_presentations_ipmc_2008.pdf
4. Djingarey MH, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, Kandolo D, et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine. 2012;30(Suppl 2):B40–5. http://dx.doi.org/10.1016/j.vaccine.2011.12.073
5. Novak RT, Kambou JL, Diomande FV, Tarbangdo TF, Ouedraogo-Traore R, Sangare L, et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis. 2012;12:757–64. http://dx.doi.org/10.1016/S1473-3099(12)70168-8
6. Delrieu I, Yaro S, Tamekloe TA, Njanpop-Lafourcade BM, Tall H, Jaillard P, et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS ONE. 2011;6:e19513. http://dx.doi.org/10.1371/journal.pone.0019513
7. Lingappa JR, Al-Rabeeh AM, Hajjeh R, Mustafa T, Fatani A, Al-Bassam T, et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis. 2003;9:665–71. http://dx.doi.org/10.3201/eid0906.020565
8. Issa M, Molling P, Unemo M, Backman M, Sulasaim N, et al. Neisseria meningitidis serogroup W-135 isolated from healthy carriers and patients in Sudan during the Hajj in 2000. Scand J Infect Dis. 2003;35:230–3.
9. Matsika-Claquin MD, Perrocheau A, Taha MK, Levy-Bruhl D, Renaud P, Alonso JM, et al. Meningococcal W135 infection epidemics associated with pilgrimage to Mecca in 2000 [in French]. Presse Med. 2001;30:1529–34.
10. Meningococcal meningitis. Wkly Epidemiol Rec. 2003;78:294–6.
11. Traoré Y, Njanpop-Lafourcade BM, Adjogble KL, Lourd M, Yaro S, Nacro B, et al. The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002–2005. Clin Infect Dis. 2006;43:817–22. http://dx.doi.org/10.1086/507339
12. Forgor AA, Leimkugel J, Hodgson A, Bugri A, Dangy JP, Gagneux S, et al. Emergence of W135 meningococcal meningitis in Ghana. Trop Med Int Health. 2005;10:1229–34. http://dx.doi.org/10.1111/j.1365-3156.2005.01520.x
13. Collard JM, Maman Z, Yacouba H, Djibo S, Nicolas P, Jusot IF, et al. Increase in Neisseria meningitidis serogroup W135, Niger, 2010. Emerg Infect Dis. 2010;16:1496–8. http://dx.doi.org/10.3201/eid1609.100510
14. Massenet D, Inrombe J, Mevoula DE, Nicolas P. Serogroup W135 meningococcal meningitis, northern Cameroon, 2007–2008. Emerg Infect Dis. 2009;15:340–2. http://dx.doi.org/10.3201/eid1502.080988
15. Meningococcal disease in countries of the African meningitis belt, 2012. Emerging needs and future perspectives. Wkly Epidemiol Rec. 2013;88:129–36.
16. Mothershed EA, Sacchi CT, Whitney AM, Barnett GA, Ajello GW, Schmink S, et al. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol. 2004;42:320–8. http://dx.doi.org/10.1128/JCM.42.1.320-328.2004
17. World Health Organization. Laboratory methods for the diagnosis of meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. 2nd ed. Geneva: The Organization; 2011.
18. World Health Organization. Control of epidemic meningococcal disease. WHO practical guidelines. 2nd ed. Geneva: The Organization; 1998.
19. Meats E, Feil EJ, Stringer S, Cody AJ, Goldstein R, Kroll JS, et al. Characterization of encapsulated and nonencapsulated Haemophilus influenzae and determination of phylogenetic relationships by multilocus sequence typing. J Clin Microbiol. 2003;41:1623–36. http://dx.doi.org/10.1128/JCM.41.4.1623-1636.2003
20. Leake JA, Kone ML, Yada AA, Barry LF, Traore G, Ware A, et al. Early detection and response to meningococcal disease epidemics in sub-Saharan Africa: appraisal of the WHO strategy. Bull World Health Organ. 2002;80:342–9.
21. Nathan N, Rose AM, Legros D, Tiendrebeogo SR, Bachy C, Bjorlov E, et al. Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis. 2007;13:920–3. http://dx.doi.org/10.3201/cid.1306.060940
22. Mayer LW, Reeves MW, Al-Hamdan N, Sacchi CT, Taha MK, Ajello GW, et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electrophoretic type-37 complex. J Infect Dis. 2002;185:1596–605. http://dx.doi.org/10.1086/340414
23. Kristiansen PA, Diomandé F, Ba AK, Sanou I, Ouédraogo AS, Ouédraogo R, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis. 2013;56:354–63. http://dx.doi.org/10.1093/cid/cis892

24. Yaro S, Traoré Y, Tarnagda Z, Sangaré L, Njanpop Lafourcade BM, Drabo A, et al. Meningococcal carriage and immunity in western Burkina Faso, 2003. Vaccine. 2007;25(Suppl 1):A42–6. http://dx.doi.org/10.1016/j.vaccine.2007.04.039

25. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis. 2007;196:1346–54. http://dx.doi.org/10.1086/521626

26. Trotter CL, Ramsay ME, Gray S, Fox A, Kaczmarski E. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis. 2006;6:616–7, author reply 7–8. http://dx.doi.org/10.1016/S1473-3099(06)70584-9

27. Ladhani SN, Luciarne J, Newbold LS, Gray SJ, Carr AD, Findlow J, et al. Invasive meningococcal capsular group Y disease, England and Wales, 2007–2009. Emerg Infect Dis. 2012;18:63–70. http://dx.doi.org/10.3201/eid1801.110901

Address for correspondence: Jessica R MacNeil, Centers for Disease Control and Prevention, Mailstop C25, 1600 Clifton Rd, NE, Atlanta, GA 30333, USA; email: aji8@cdc.gov
This content is in the Public Domain.